Effectiveness of meningococcal serogroup C vaccine programmes

Raymond Borrow*, Raquel Abad, Caroline Trotter, Fiona R.M. van der Klis, Julio A. Vazquez

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

77 Citations (Scopus)


Since the introduction of monovalent meningococcal serogroup C (MenC) glycoconjugate (MCC) vaccines and the implementation of national vaccination programmes, the incidence of MenC disease has declined markedly as a result of effective short-term vaccination and reduction in acquisition of MenC carriage leading to herd protection. Monovalent and quadrivalent conjugate vaccines are commonly used vaccines to provide protection against MenC disease worldwide. Studies have demonstrated that MCC vaccination confers protection in infancy (0-12 months) from the first dose but this is only short-term. NeisVac-C® has the greatest longevity of the currently licensed MCC vaccines in terms of antibody persistence, however antibody levels have been found to fall rapidly after early infant vaccination with two doses of all MCC vaccines - necessitating a booster at ~12 months. In toddlers, only one dose of the MCC vaccine is required for routine immunization. If herd protection wanes following catch-up campaigns, many children may become vulnerable to infection. This has led many to question whether an adolescent booster is also required.

Original languageEnglish
Pages (from-to)4477-4486
Number of pages10
Issue number41
Publication statusPublished - 23 Sept 2013

Bibliographical note

Funding Information:
This paper was supported by an educational grant from Baxter Healthcare. Representatives of Baxter Healthcare had no role in gathering, analysing, or interpreting the information presented. Editorial assistance was provided by Touch Medical Communications.


  • Children
  • Immunologic memory
  • Meningococcal serogroup C vaccine
  • Monovalent glycoconjugate vaccine
  • Vaccine effectiveness


Dive into the research topics of 'Effectiveness of meningococcal serogroup C vaccine programmes'. Together they form a unique fingerprint.

Cite this